Preceding blocking experiments revealed that Lirilumab significantly inhibited the binding of CD158a and CD158b monoclonal antibodies to blood- as well as tumor-derived NK-cells at a concentration of 30 μg/ml (Fig. 3b). Here, KIR2DL3 is linked to neoplasm.